1. Home
  2. PLYM vs NAMSW Comparison

PLYM vs NAMSW Comparison

Compare PLYM & NAMSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLYM
  • NAMSW
  • Stock Information
  • Founded
  • PLYM N/A
  • NAMSW N/A
  • Country
  • PLYM United States
  • NAMSW Netherlands
  • Employees
  • PLYM N/A
  • NAMSW 29
  • Industry
  • PLYM Real Estate Investment Trusts
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • Sector
  • PLYM Real Estate
  • NAMSW Health Care
  • Exchange
  • PLYM Nasdaq
  • NAMSW Nasdaq
  • Market Cap
  • PLYM N/A
  • NAMSW N/A
  • IPO Year
  • PLYM 2017
  • NAMSW N/A
  • Fundamental
  • Price
  • PLYM $23.73
  • NAMSW $9.45
  • Analyst Decision
  • PLYM Buy
  • NAMSW
  • Analyst Count
  • PLYM 5
  • NAMSW 0
  • Target Price
  • PLYM $24.60
  • NAMSW N/A
  • AVG Volume (30 Days)
  • PLYM 221.5K
  • NAMSW N/A
  • Earning Date
  • PLYM 07-31-2024
  • NAMSW N/A
  • Dividend Yield
  • PLYM 4.07%
  • NAMSW N/A
  • EPS Growth
  • PLYM N/A
  • NAMSW N/A
  • EPS
  • PLYM 0.44
  • NAMSW N/A
  • Revenue
  • PLYM $200,676,000.00
  • NAMSW N/A
  • Revenue This Year
  • PLYM $4.83
  • NAMSW N/A
  • Revenue Next Year
  • PLYM $5.96
  • NAMSW N/A
  • P/E Ratio
  • PLYM $53.48
  • NAMSW N/A
  • Revenue Growth
  • PLYM 5.55
  • NAMSW N/A
  • 52 Week Low
  • PLYM $19.21
  • NAMSW N/A
  • 52 Week High
  • PLYM $25.55
  • NAMSW N/A
  • Technical
  • Relative Strength Index (RSI)
  • PLYM 76.27
  • NAMSW 50.58
  • Support Level
  • PLYM $21.23
  • NAMSW $9.40
  • Resistance Level
  • PLYM $21.74
  • NAMSW $10.14
  • Average True Range (ATR)
  • PLYM 0.38
  • NAMSW 0.48
  • MACD
  • PLYM 0.24
  • NAMSW 0.06
  • Stochastic Oscillator
  • PLYM 99.34
  • NAMSW 29.67

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: